Literature DB >> 33596306

Schlafen 11 Is a Novel Target for Mucosal Regeneration in Ulcerative Colitis.

Sho Watanabe1, Ryu Nishimura1, Tomoaki Shirasaki1, Nobuhiro Katsukura1, Shuji Hibiya1, Susumu Kirimura2, Mariko Negi3, Ryuichi Okamoto1,4, Yuka Matsumoto5, Tetsuya Nakamura5, Mamoru Watanabe1,6, Kiichiro Tsuchiya1.   

Abstract

BACKGROUND AND AIMS: Ulcerative colitis [UC] is a chronic inflammatory disease of the colon with an intractable course. Although the goal of UC therapy is to achieve mucosal healing, the pathogenesis of mucosal injury caused by chronic inflammation remains unknown. We therefore aim to elucidate molecular mechanisms of mucosal injury by establishing in vitro and in vivo humanised UC-mimicking models.
METHODS: An in vitro model using human colon organoids was established by 60 weeks of inflammatory stimulation. The key gene for mucosal injury caused by long-term inflammation was identified by microarray analysis. An in vivo model was established by xenotransplantation of organoids into mouse colonic mucosa.
RESULTS: An in vitro model demonstrated that long-term inflammation induced irrecoverable changes in organoids: inflammatory response and apoptosis with oxidative stress and suppression of cell viability. This model also mimicked organoids derived from patients with UC at the gene expression and phenotype levels. Microarray analysis revealed Schlafen11 [SLFN11] was irreversibly induced by long-term inflammation. Consistently, SLFN11 was highly expressed in UC mucosa but absent in normal mucosa. The knockdown of SLFN11 [SLFN11-KD] suppressed apoptosis of intestinal epithelial cells [IECs] induced by inflammation. Moreover, SLFN11-KD improved the take rates of xenotransplantation and induced the regenerative changes of crypts observed in patients with UC in remission.
CONCLUSIONS: In vitro and in vivo UC-mimicking models were uniquely established using human colonic organoids. They revealed that SLFN11 is significant for mucosal injury in UC, and demonstrated its potential as a novel target for mucosal regeneration.
© The Author(s) 2021. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Inflammatory bowel disease; SLFN11; in vivo human model

Mesh:

Substances:

Year:  2021        PMID: 33596306     DOI: 10.1093/ecco-jcc/jjab032

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  4 in total

1.  Prognostic impact of Schlafen 11 in bladder cancer patients treated with platinum-based chemotherapy.

Authors:  Daiki Taniyama; Naoya Sakamoto; Tsuyoshi Takashima; Masahiko Takeda; Quoc Thang Pham; Shoichi Ukai; Ryota Maruyama; Kenji Harada; Takashi Babasaki; Yohei Sekino; Tetsutaro Hayashi; Kazuhiro Sentani; Yves Pommier; Junko Murai; Wataru Yasui
Journal:  Cancer Sci       Date:  2021-12-07       Impact factor: 6.716

2.  Integrated Analysis of Microarray Studies to Identify Novel Diagnostic Markers in Bladder Pain Syndrome/Interstitial Cystitis with Hunner Lesion.

Authors:  Xiao-Feng Cheng; Zhen-Hao Zeng; Wen Deng; Yi-Fu Liu; Xiao-Chen Zhou; Cheng Zhang; Gong-Xian Wang
Journal:  Int J Gen Med       Date:  2022-03-19

3.  SLFN11's surveillance role in protein homeostasis.

Authors:  Yasuhisa Murai; Ukhyun Jo; Yasuhiro Arakawa; Naoko Takebe; Yves Pommier
Journal:  Oncoscience       Date:  2022-07-25

4.  Influence of chronic inflammation on the malignant phenotypes and the plasticity of colorectal cancer cells.

Authors:  Sho Watanabe; Shuji Hibiya; Nobuhiro Katsukura; Sayuki Kitagawa; Ayako Sato; Ryuichi Okamoto; Mamoru Watanabe; Kiichiro Tsuchiya
Journal:  Biochem Biophys Rep       Date:  2021-05-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.